Biotech News - Rubicon Genomics Forms New Scientific Advisory Board to Reflect Its Developments

Rubicon Genomics Forms New Scientific Advisory Board to Reflect Its
Developments in Molecular Diagnostics


Dr. Arul M. Chinnaiyan Appointed First Advisory Board Member

Rubicon Genomics today announced the formation of a new Scientific
Advisory Board to support its recent advances in cancer molecular
diagnostics.

The company appointed Arul M. Chinnaiyan, M.D., Ph.D. as its first
new Molecular Diagnostics Scientific Advisory Board Member. Dr.
Chinnaiyan is the S.P. Hicks Endowed Professor of Pathology and
Associate Professor of Urology at the University of Michigan Medical
School. He is the co-Director of the Division of Pathology
Informatics and Director of the Cancer Bioinformatics Core. He is a
recognized leader in the field and has led the characterization
of a number of biomarkers of prostate cancer including AMACR, EZH2,
and hepsin. Most recently, his laboratory identified gene fusion of
TMPRSS2 to ETS family of transcription factors in prostate cancer,
potentially redefining the molecular basis of prostate cancer as
well as other common epithelial cancers. Dr. Chinnaiyan has
received numerous awards, authored more than 100 publications, holds
several U.S. patents, and is funded by the National Institute of
Health, the American Cancer Society, and the Department of
Defense.

"We feel both privileged and fortunate to have Dr. Chinnaiyan
joining our New Scientific Advisory Board for Molecular
Diagnostics," said Fred G. Beyerlein, President & CEO of
Rubicon. "Our association with Dr. Chinnaiyan, his labs, and the
University of Michigan spans several years and has proven to
be a fruitful collaboration. Our mutual interests in developing
breakthroughs in the early detection, monitoring, and deeper
understanding of cancer have always been in alignment. We are
looking forward to his insights and contributions as a member of our
newly formed Molecular Diagnostics Scientific Advisory Board."

About Rubicon Genomics, Inc.
Rubicon, located in Ann Arbor, MI, is focused on the development of
highly sensitive and highly specific non-invasive tests for cancer
and other diseases using its proprietary MethylPlex(TM) technology.
Utilizing the MethylPlex platform the company has discovered and
developed proprietary tumor markers and patterns of tumor markers.
The Company is a leader in the development of breakthrough methods
of detecting the pattern of genetic, epigenetic, and expression
changes in tumor cells as well as developing kits and services to
facilitate gene-based research and drug development. For additional
information please visit the Rubicon website:
http://rubicongenomics.com or
telephone 734-677-6210.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/